

Tomohiko Fukuda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9918052/publications.pdf>

Version: 2024-02-01

18
papers

477
citations

687363

13
h-index

839539

18
g-index

18
all docs

18
docs citations

18
times ranked

792
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Promoting Effect of BMP Signaling in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7882.	4.1	14
2	BMP2-induction of FN14 promotes protumorigenic signaling in gynecologic cancer cells. <i>Cellular Signalling</i> , 2021, 87, 110146.	3.6	11
3	BMP signaling is a therapeutic target in ovarian cancer. <i>Cell Death Discovery</i> , 2020, 6, 139.	4.7	22
4	Kaempferol, a natural dietary flavonoid, suppresses 17 β -estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer. <i>Oncology Letters</i> , 2018, 16, 6195-6201.	1.8	31
5	The Emerging Role of FOXL2 in Regulating the Transcriptional Activation Function of Estrogen Receptor β : An Insight Into Ovarian Folliculogenesis. <i>Reproductive Sciences</i> , 2017, 24, 133-141.	2.5	7
6	MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. <i>Oncotarget</i> , 2016, 7, 75328-75338.	1.8	33
7	Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 564-569.	1.4	35
8	Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells. <i>Oncology Letters</i> , 2016, 12, 2560-2566.	1.8	31
9	Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 757-762.	1.3	17
10	Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. <i>Oncotarget</i> , 2016, 7, 29577-29591.	1.8	18
11	HAND2-mediated proteolysis negatively regulates the function of estrogen receptor α . <i>Molecular Medicine Reports</i> , 2015, 12, 5538-5544.	2.4	9
12	Putative tumor suppression function of SIRT6 in endometrial cancer. <i>FEBS Letters</i> , 2015, 589, 2274-2281.	2.8	31
13	Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2015, 113, 1477-1483.	6.4	30
14	CCAR2 negatively regulates nuclear receptor LXR α by competing with SIRT1 deacetylase. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 149, 80-88.	2.5	10
15	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2015, 138, 323-331.	1.4	19
16	The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. <i>Gynecologic Oncology</i> , 2015, 137, 538-545.	1.4	67
17	PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1- α /VEGF pathway in endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 174-180.	1.4	52
18	Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423. <i>PLoS ONE</i> , 2014, 9, e87220.	2.5	40